Latest Publications
Artugen Announces Oral and Poster Presentations at the 30th ECCMID
The European Congress of Clinical Microbiology and Infectious Diseases happens from 18–21 April in Paris
Artugen Therapeutics Announces First Patient Dosed with ART24
March 12, 2020 Artugen’s first clinical product candidate for prevention of recurrence of Clostridium difficile infection - ART24 granted Fast Track Designation - First Patient Dosed
NIH: “Probiotic bacteria block harmful microbe”
NIAID Director Dr. Anthony S. Fauci talks about the use of bacteria as drugs.
CDC: 2019 AR Threats Report
A newly published CDC report includes the latest national death and infection estimates that underscore the continued threat of CDI in the U.S.
FDA’s Strategic Approach for Combating Antimicrobial Resistance
Ex-FDA Commissioner Scott Gottlieb's talk on FDA antimicrobial resistance strategies highlights the use of innovative approaches including Live Biotherapeutic Products.